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Abstract
Objective. To confirm validity of the Self-administered Comorbidity Questionnaire modified for patients with SpA
(mSCQ), and assess whether validity improves when adding items on extra-articular manifestations (EAMs), i.e. uveitis,
psoriasis, and IBD, and osteoporosis and fractures.
Methods. Data from the Assessment in SpondyloArthritis international Society COMOrbidities in SPondyloArthritis
study were used. Criterion validity of presence of EAMs, osteoporosis and fractures was assessed as agreement
(kappa) between patients’ self-reported and physician-confirmed disease. Construct validity of the mSCQ including
EAMs, osteoporosis and/or fractures (SpA-SCQ) was assessed by testing hypotheses about correlations with demo-
graphics, physical function, work ability, health utility and disease activity, and was compared with construct validity of
the rheumatic disease comorbidity index.
Results. In total, 3984 patients contributed to the analyses. Agreement between patient-reported and physician-re-
ported EAMs was substantial to almost perfect (uveitis Œ = 0.81, IBD Œ = 0.73, psoriasis Œ = 0.86). Agreement for osteo-
porosis (Œ = 0.38) and fractures (Œ = 0.39) was fair. As hypothesized, the mSCQ correlated moderately to weakly with age,
physical function, work limitations and health utility, and very weakly with disease activity. In contrast to our hypothesis,
adding EAMs, osteoporosis and/or fractures to the mSCQ decreased correlations with several external constructs,
especially among patients with peripheral SpA. Correlations with the different constructs were stronger for the both
mSCQ and SpA-SCQ (rBASFI = 0.34; rEQ-5D =0.33) compared with the rheumatic disease comorbidity index (rBASFI = 0.24;
rEQ-5D =0.21).
Conclusion. The mSCQ is a valid self-report instrument to assess the influence of comorbidities on health outcomes in
patients with SpA. Adding EAMs and/or osteoporosis or fractures does not improve validity of the mSCQ.
Key words: spondyloarthritis, axial spondyloarthritis, peripheral spondyloarthritis, comorbidity, extra-articular
manifestations, comorbidity questionnaire, validity
Rheumatology key messages
. The mSCQ is a valid instrument to assess comorbidity in patients with SpA.
. Patients with SpA can accurately report extra-articular manifestations.
. Adding EAMs or fractures to the SpA-mSCQ does not improve validity of the questionnaire.
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Introduction
In addition to axial and peripheral joint disease, patients
with spondyloarthritis (SpA) can have one or more extra-
articular manifestations (EAMs), including acute anterior
uveitis (AAU), psoriasis and IBD [1]. These EAMs are
recognized to be part of the SpA disease concept, and
contribute to the diagnosis of SpA [2], as reflected in the
current classification criteria [3, 4]. Patients with SpA may
also develop diseases that are not related to the SpA con-
cept, but that may co-exist with the main disease, as a
consequence of the disease process or its treatment, and
which are called comorbidities. Both, EAMs and comor-
bidities have been associated with impaired physical and
mental functioning, restricted participation in social roles
and increased health care costs [57]. It has been shown
that EAMs and comorbidities influence the choice of drug
treatment [8] and contribute to the complexity of manage-
ment of patients [9].
To assess the influence of comorbidities on functioning
and health in patients with ankylosing spondylitis (AS), the
self-administered comorbidity questionnaire (SCQ) was
validated in 98 patients with AS in the Outcome in AS
International Study (OASIS) [10, 11]. This study showed
evidence for criterion and construct validity of the SCQ
in patients with long-standing AS, who fulfilled the New
York criteria for AS and were under care of a rheumatolo-
gist in three tertiary centres in Europe. The validity im-
proved after removing rheumatic items (chronic
rheumatic disease, back pain and osteoarthritis) from
the original questionnaire, which led to the development
of a modified SCQ (mSCQ) for AS [10]. However, it is not
known whether the mSCQ has also validity in a broader,
more heterogeneous group of patients with axial (with and
without radiographic involvement) as well as peripheral
SpA. Moreover, as EAMs frequently occur in this popula-
tion and can impact health outcomes, it can be expected
that adding EAMs to the mSCQ may improve the validity
of the questionnaire. Furthermore, the mSCQ includes
common comorbidities, such as cardiovascular disease,
but not yet comorbidities that are more frequent in SpA
compared with the general population, such as fractures
and osteoporosis, and which might impact functioning
and health in SpA.
Therefore, the aims of the current study were to confirm
the construct validity of the mSCQ in a heterogeneous
group of patients with SpA, to evaluate whether EAMs,
osteoporosis and fractures can be reliably assessed
using self-report, and to assess whether ‘adding’ EAMs,
osteoporosis and/or fractures improves the construct val-




This study was conducted using the Assessment
in SpondyloArthritis international Society (ASAS)
COMOrbidities in Spondyloarthritis (ASAS-COMOSPA)
dataset, which has been described elsewhere [12]. In
summary, ASAS-COMOSPA is an observational, cross-
sectional, multicentre, international study. In total, 22
countries participated and included consecutive patients
of at least 18 years with a clinical diagnosis of axial SpA
(axSpA) or peripheral SpA (pSpA) according to the
rheumatologist. Patients had to be able to understand
and complete the questionnaire. The study was con-
ducted according to guidelines for good clinical practice
in each country, with all local ethics committees approving
the ASAS-COMOSPA study protocol. All patients signed
informed consent before enrolment [12].
Assessments
Demographics and disease characteristics
For each patient, demographics and disease characteris-
tics, such as axial or peripheral involvement, arthritis and
enthesitis, were collected. Disease activity was measured
by the ASDAS including CRP [13], physical function by the
BASFI [14], well-being by the patient global assessment
score [15], and health utility by the EuroQoL 5 dimensions
questionnaire (EQ-5D) [16]. Restrictions in paid or unpaid
work in the past 7 days due to health problems were as-
sessed using the Work Productivity and Activity
Impairment questionnaire [17].
Comorbidities and EAMs
The presence or history of commonly occurring and im-
portant comorbidities in SpA was collected by the study
investigator or research nurse during a face-to-face inter-
view at the study visit, ascertained by a review of the
medical record and current medication use.
Comorbidities included ischaemic cardiovascular disease
(myocardial infarction and stroke), cancer (lung, colon,
skin, breast and cervix for women, prostate for men,
and lymphoma), osteoporosis (defined as (i) a T-score
<2.5 S.D. at either the total hip or lumbar spine or the
femoral neck, (ii) a history of a vertebral or peripheral non-
traumatic fracture, (iii) a past history or current treatment
with a specific anti-osteoporotic drug, or (iv) a history of
diagnosis of secondary osteoporosis), gastrointestinal
disease (a history of gastroduodenal ulcer and diverticu-
litis), hypertension and diabetes. The presence or history
of EAMs [AAU, IBD (Crohn’s disease or ulcerative colitis)
and psoriasis, diagnosed by an opthalmologist for AAU or
physcian for IBD and psoriasis] was obtained by the study
investigator by review of the medical record and by inter-
viewing the patient.
The mSCQ
The mSCQ is a self-reported questionnaire [10]. The
mSCQ asks whether the patient suffers currently from
one or more of 10 medical conditions (heart disease,
hypertension, lung disease, diabetes, ulcer or stomach
disease, kidney disease, liver disease, anaemia or other
blood disease, cancer, and depression), and an option to
add three other not pre-specified medical problems [11].
The patient is asked to indicate for each condition if it is
present (yes/no), is currently treated (yes/no), and/or
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imposes functional limitations (yes/no). Every ‘yes’ is
given 1 point contributing to a maximum score of 39. For
the present study, different SpA-specific versions of the
mSCQ (SpA-SCQ) were computed by adding uveitis,
psoriasis, IBD, with or without osteoporosis and/or frac-
tures. The SpA-SCQ versions are scored similarly to the
mSCQ but due to additional items, the score for the most
extensive version ranges from 0 to 54. The mSCQ and
questions on EAMs were translated by the national prin-
cipal investigators in the appropriate language, in which
they were instructed to use layman’s terms (e.g. add short
descriptions to the name of the condition) in order to make
the mSCQ as clear as possible for patients.
The RDCI
The Rheumatic Disease Comorbidity Index (RDCI) is a
validated instrument to reflect the burden of comorbidity
on functioning and mortality [18]. The RDCI (score 09) is
calculated using the following formula: 2  lung disease +
[2  (heart attack, other CV, or stroke) or 1  hyperten-
sion] + fracture + depression + diabetes + cancer + (ulcer
or stomach problem). In the present study, information on
physician-reported comorbidities were used to calculate
the RDCI, except for depression that was based on pa-
tients’ self-reporting, because this item was not included
in the CRF of the study investigator in COMOSPA.
Statistics
Descriptive statistics were used to characterize the study
sample, using mean with standard deviation for continu-
ous data, and frequencies were calculated for dichotom-
ous data.
Criterion validity
Agreement between self-reported EAMs, osteoporosis
and fractures with comorbidities reported by the study
investigator was evaluated using Cohen’s kappa. A
kappa value of <0.001 was considered as poor agree-
ment, 0.0010.20 as slight, 0.210.40 as fair, 0.410.60
as moderate, 0.610.80 as substantial and 0.811.00 as
almost perfect agreement [19].
Construct validity
For construct validity, the correlation between comorbid-
ity scores and continuous external constructs was evalu-
ated using Spearman’s correlation coefficient. Correlation
coefficients of 0.010.20 were considered as very weak,
0.210.40 as weak, 0.410.75 as moderate and above
0.75 as strong [20]. First, the correlations between the
different versions of the mSCQ and the RDCI were calcu-
lated and (very) strong correlations would indicate that
both approaches to assess comorbidities would actually
be interchangeable. Second, the predetermined hypoth-
esis was tested that the mSCQ correlates moderately with
age, physical function (measured with the BASFI), health
utility (measured with the EQ-5D using the French tariff for
all patients), patient’s global assessment of well-being as-
sessment of well-being, productivity at work and impact
on regular activities, but very weak with disease activity
(measured with the ASDAS-CRP). Next, the correlations
with the constructs of the different versions of the SpA-
SCQ (mSCQ + EAMs, mSCQ + osteoporosis + fractures,
and mSCQ + EAMs + osteoporosis and/or fractures) and
the RDCI were compared with the mSCQ. The predeter-
mined hypothesis was that SpA-SCQ versions would cor-
relate better with physical function, quality of life, work
ability and patient’s global score of well-being. A change
of 10% of the correlation coefficient was considered as a
relevant improvement.
Analyses were repeated for the subgroups of patients
fulfilling either the ASAS axSpA or pSpA criteria.
Furthermore, an additional explorative analysis was per-
formed to understand whether there are differences in
validity between different regions of the world. For all out-
comes, differences in correlation coefficients of 10% be-
tween groups were considered as relevant. All analyses
were performed using SPSS Statistics version 20.0 (IBM
Corp., Armonk, NY, USA).
Results
In total 4028 patients from 22 countries were included in
ASAS-COMOSPA. Forty-four patients were excluded be-
cause all data except identification numbers were miss-
ing. Therefore, 3984 patients contributed to the current
analysis [12]. Table 1 presents the clinical and demo-
graphic characteristics for the total group, and for
axSpA and pSpA separately. The mean (S.D.) age was
43.6 (14.0) years, 2563 were male patients (65.0%), and
the mean (S.D.) disease duration was 8.2 (9.3) years. In
total, 2955 (75%) patients fulfilled the ASAS criteria for
axSpA and 415 (10.4%) patients fulfilled the ASAS criteria
for pSpA; 614 (14.6%) patients did not fulfil any of the
ASAS criteria [21]. The mean mSCQ score was 1.9 (S.D.
2.7, range 022). The mean score of the mSCQ including
the three EAMs was 2.7 (S.D. 3.2, range 029), and the
mean score of the mSCQ including EAMs, osteoporosis
and fractures was 2.9 (S.D. 3.4, range 035). The mean
RCDI score was 0.6 (S.D. 1.0, range 08). Patients who
fulfilled the ASAS pSpA criteria were on average older
and reported higher comorbidity scores on both the
mSCQ and the RDCI compared with patients who fulfilled
the ASAS axSpA criteria.
Supplementary Table S1, available at Rheumatology
online, shows the baseline characteristics and mSCQ
scores per region in the world. Patients from Europe and
North America were on average older compared with
those from other regions, and reported higher comorbidity
scores.
The most frequently self-reported comorbidities were
hypertension (820 patients, 20.6%), and depression (534
patients, 13.4%) (Table 2). Examples of frequently re-
ported ‘other medical conditions’ were fibromyalgia (63
patients, 1.6%), thyroid disease (46 patients, 1.2%) and
hypercholesterolaemia (38 patients, 1.0%). Hypertension
was the comorbidity for which use of medication was re-
ported most often (18.6%), and depression most fre-
quently limited functioning (4.4%). Psoriasis was the
most frequently reported EAM (22.1%), followed by uveitis
(18.8%) and IBD (7.2%). Limitations in functioning caused
1634 https://academic.oup.com/rheumatology
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SpA (n = 415)
Male gender, n (%) 2563 (65.0) 1996 (67.5) 225 (54.2)
Age, mean (S.D.), years 43.6 (14.0) 41.7 (13.2) 51.1 (14.0)
Disease duration, mean (S.D.), years 8.2 (9.3) 8.6 (9.7) 6.4 (7.6)






Current smoker, n (%) 914 (22.9) 717 (24.3) 66 (15.9)
BMI (kg/m2), mean (S.D.) 26.1 (5.7) 25.9 (5.6) 27.6 (6.4)
Currently employed, n (%) 2325 (58.4) 1766 (59.8) 228 (54.9)
ASDAS-CRP, mean (S.D.) 2.0 (1.1) 2.0 (1.1) 2.0 (1.0)
BASFI (010), mean (S.D.) 3.0 (2.7) 3.1 (2.7) 2.8 (2.6)
EQ-5D (01), mean (S.D.) 0.59 (0.34) 0.58 (0.34) 0.57 (0.34)
Global well-being (010), mean (S.D.) 4.1 (2.6) 4.1 (2.5) 4.1 (2.6)
WPAI, impact on work productivity (010), mean
(S.D.)a,b
2.8 (2.6) 2.8 (2.6) 2.9 (3.0)
Impact on daily activities (010), mean (S.D.)a 3.8 (2.9) 3.8 (2.9) 3.9 (2.9)
History of uveitis, n (%) 769 (19.3) 653 (22.1) 44 (10.6)
History of psoriasis, n (%) 841 (21.1) 371 (12.6) 240 (57.8)
History of IBD, n (%) 208 (5.2) 157 (5.3) 17 (4.1)
mSCQ (039), mean (S.D.); median (range) 1.9 (2.7); 1 (022) 1.8 (2.6); 0 (021) 2.5 (3.2); 2 (020)
mSCQ + EAMs (048), mean (S.D.); median
(range)
2.7 (3.2); 2 (029) 2.4 (3.0); 1 (024) 3.8 (3.8); 3 (029)
mSCQ + osteoporosis + fractures (045), mean
(S.D.); median (range)
2.1 (3.0); 1 (026) 2.0 (2.8); 1 (024) 2.7 (3.6); 2 (026)
mSCQ + EAMS + osteoporosis + fractures
(054), mean (S.D.); median (range)
2.9 (3.4); 2 (035) 2.6 (3.2); 2 (027) 4.1 (4.2); 3 (035)
RDCI (09), mean (S.D.); median (range) 0.6 (1.0); 0 (08) 0.5 (1.0); 0 (08) 0.9 (1.2); 0 (08)
aMeasured with the WPAI. bOnly in patients currently employed (n = 2325). ASAS: Assessment SpondyloArthritis international
Society; EAM: extra-articular manifestation; EQ-5D: Euroqol 5 D; mSCQ: modified self-administered comorbidity questionnaire;
SpA: spondyloarthritis; RDCI: rheumatic disease comorbidity instrument; WPAI: work productivity and activity impairment.
TABLE 2 Patients’ responses on SpA-SCQ (n = 3984)
Response Present, n (%) Treatment, n (%) Limitations, n (%)
Heart disease 220 (5.5) 177 (4.4) 85 (2.1)
Hypertension 820 (20.6) 743 (18.6) 100 (2.5)
Lung disease 159 (4.0) 120 (3.0) 65 (1.6)
Diabetes 201 (5.0) 181 (4.5) 59 (1.5)
Ulcer or stomach disease 421 (10.6) 346 (8.7) 82 (2.1)
Kidney disease 120 (3.0) 65 (1.6) 17 (0.4)
Liver disease 129 (3.2) 68 (1.7) 10 (0.3)
Anaemia/other blood disease 283 (7.1) 134 (3.4) 61 (1.5)
Cancer 60 (1.5) 39 (1.0) 15 (0.4)
Depression 534 (13.4) 268 (6.7) 177 (4.4)
Other medical problem 1a 590 (14.8) 448 (11.2) 278 (7.0)
Other medical problem 2a 170 (4.3) 112 (2.8) 57 (1.4)
Other medical problem 3a 60 (1.5) 44 (1.1) 32 (0.8)
Uveitis 747 (18.8) 110 (2.8) 174 (4.4)
Psoriasis 880 (22.1) 483 (12.1) 175 (4.4)
Inflammatory bowel disease 288 (7.2) 115 (2.9) 73 (1.8)
Osteoporosis 295 (7.4) 203 (5.1) 74 (1.9)
Fractures 195 (4.9) 88 (2.2) 60 (1.5)
aThe SCQ includes the option to fill in one to three other non-specified medical problems. SpA-SCQ: spondyloarthritis self-
administered comorbidity questionnaire.
https://academic.oup.com/rheumatology 1635
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by EAMs were reported by 4.4% of patients with uveitis
and psoriasis, and by 1.8% of patients with IBD.
Criterion validity
Table 3 shows the frequency of self-reported EAMs,
osteoporosis and fractures compared with the frequency
of these conditions according to the study investigator,
and agreement (kappa) between both. The agreement
was almost perfect for uveitis (Œ = 0.81) and psoriasis
(Œ = 0.86), substantial for inflammatory bowel disease
(Œ = 0.73), and fair for osteoporosis and fractures
(Œ = 0.38 and Œ = 0.39, respectively). Agreement was com-
parable for axial and peripheral SpA. Supplementary
Table S2, available at Rheumatology online, shows the
criterion validity per region in the world. For uveitis and
IBD, the lowest kappa values were found in North Africa.
Construct validity
The correlation between the mSCQ and the SpA-SCQ
(including EAMS and osteoporosis and/or fractures) was
0.79, between the mSCQ and RDCI 0.57, and between the
SpA-SCQ and RDCI 0.54.
Table 4 shows the correlations of the mSCQ, the differ-
ent SpA-SCQ versions and RDCI with different external
constructs in the total group, and in the subgroups of pa-
tients with axSpA and pSpA. Supplementary Table S3,
available at Rheumatology online, shows the construct
validity by region in the world.
As hypothesized, the mSCQ correlated weakly to mod-
erately with age and physical functioning, quality of life
and patient’s global. Correlation between the mSCQ and
disease activity was very weak.
When adding EAMs to the mSCQ, correlation with age
became better. However, in contrast to our hypothesis,
correlations with patient’s global assessment of well-
being, productivity at work and influence on daily activities
became weaker. Correlations with BASFI and EQ-5D did
not change. When adding osteoporosis or fractures to the
mSCQ, no change in correlations was observed.
In subanalyses of patients with axSpA and pSpA, a
stronger correlation of the mSCQ with BASFI was found
in patients with pSpA, whereas in patients with axSpA a
stronger correlation with EQ-5D was found. When EAMs
were added to the mSCQ, correlations with most variables
became weaker in patients with pSpA, whereas only cor-
relation with productivity at work and disease activity
became weaker in axSpA.
The RDCI, finally, showed weaker correlations with the
different external constructs than the mSCQ and SpA-
SCQ, except the correlation with age, which was stronger
for the RDCI. For the RDCI, most correlations were stron-
ger in pSpA patients compared with axSpA patients.
Construct validity of the different versions of the mSCQ
with BASFI, EQ-5D and ASDAS-CRP were lower in Asia
and North Africa, compared with other parts of the world.
Discussion
The present study confirms that the mSCQ is a valid in-
strument to assess the impact of comorbidities on phys-
ical functioning and quality of life in a real life multinational
group of patients diagnosed with axSpA or pSpA. The
mSCQ showed stronger correlations with different health
outcomes, except for age, compared with the RDCI.
Furthermore, we showed that patients can accurately
report EAMs, but agreement between self-reported and
physician-reported osteoporosis and fractures was
weak. Finally, adding EAMs and/or osteoporosis and frac-
tures to the mSCQ (SpA-SCQ) did not improve correl-
ations with different health outcomes.
TABLE 3 Agreement between mSCQ and physician-reported EAMs and comorbidities
Self-reported, n (%) Physician reported, n (%) Kappa
All patients (n = 3984)
Uveitis 747 (18.8) 769 (19.3) 0.81
Psoriasis 880 (22.1) 841 (21.1) 0.86
Inflammatory bowel disease 288 (7.2) 208 (5.2) 0.73
Osteoporosis 295 (7.4) 529 (13.4) 0.38
Fractures 195 (4.9) 192 (4.8) 0.39
Axial SpA (n = 2955)
Uveitis 635 (21.4) 646 (21.9) 0.82
Psoriasis 394 (13.3) 369 (12.5) 0.84
Inflammatory bowel disease 225 (7.6) 155 (5.2) 0.74
Osteoporosis 202 (6.8) 387 (13.1) 0.38
Fractures 138 (4.7) 145 (4.9) 0.37
Peripheral SpA (n = 415)
Uveitis 43 (10.4) 44 (10.6) 0.76
Psoriasis 242 (58.3) 238 (57.3) 0.84
Inflammatory bowel disease 25 (6.0) 17 (4.1) 0.60
Osteoporosis 31 (7.4) 50 (12.0) 0.39
Fractures 18 (4.3) 12 (2.9) 0.38
1636 https://academic.oup.com/rheumatology
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In a previous study, we showed that the mSCQ was a valid
comorbidity instrument in 98 patients with longstanding AS,
who were included in the OASIS cohort in the Netherlands,
Belgium and France [10]. In that study, the mean score of the
mSCQ was 2.9, compared with 1.9 in the present study. This
maybecausedbyahigherageofpatients in theOASIScohort
(53.9 vs 43.6 years). With respect to construct validity, slightly
different instruments were used in the OASIS study compared
with the ASAS-ComoSpA study. Correlation of the mSCQ
with the BASFI was higher in the OASIS study (0.41) com-
pared with the present study (0.31), whereas correlation be-
tween the mSCQ and quality of life was comparable (0.32 with
ASQoL and 0.33 with EQ-5D). Differences in correlations
may be caused by a more heterogeneous population, a
younger age and lower comorbidity scores in the present
study.
Although the mSCQ includes many prevalent and im-
portant comorbidities, it ignores specific diseases that
occur more frequently in patients with SpA that potentially
influence functioning and health, such as EAMs, osteopor-
osis and fractures. Along these lines, we confirm a high
proportion of patients with SpA reporting one or more
EAMs (18.8% AAU, 22.1% psoriasis and 7.2% IBD).
Obviously, the prevalence of psoriasis was higher in pa-
tients with pSpA compared with axSpA. Nevertheless,
these results are in line with a previous study that
showed high prevalence of EAMs in patients with AS
(24.5% of patients have AAU, 10.1% of patients have
psoriasis and 7.5% of patients have IBD) after a disease
duration of 20 years [22]. Differences in reported EAMs
between the different world regions were found and may
partly be caused by genetic aspects. Importantly, the
agreement between self-reported EAMs and EAMs as
confirmed by the study investigator was high for all
EAMs. This confirms that patients are highly capable of
self-reporting these conditions.
TABLE 4 Construct validity of different modifications of the mSCQ and the RDCI with health outcomes in all patients,













All patients (n = 3984)
mSCQ 0.41 0.34 0.33 0.22 0.21 0.30 0.19
mSCQ + EAMs 0.45 0.32 0.33 0.19c 0.16c 0.26c 0.16c
mSCQ + fractures 0.40 0.34 0.33 0.21 0.20 0.29 0.19
mSCQ + osteoporosis + fracture 0.41 0.34 0.33 0.22 0.21 0.30 0.19
mSCQ + EAMs + osteoporosis 0.46c 0.32 0.33 0.20 0.17c 0.27 0.16c
mSCQ + EAMs + fractures 0.45 0.32 0.33 0.19c 0.17c 0.27 0.16c
mSCQ + EAMs + osteoporosis
+ fractures
0.45 0.33 0.33 0.20 0.17c 0.27 0.17
RDCIb 0.47c 0.24c 0.21c 0.12c 0.09c 0.17c 0.10c
Patients fulfilling ASAS axSpA criteria (n = 2955)
mSCQ 0.38 0.35d 0.35d 0.21d 0.20d 0.29d 0.19d
mSCQ + EAMs 0.42c 0.34 0.34d 0.20d 0.17c,d 0.27 0.17c,d
mSCQ + fractures 0.38 0.35d 0.34d 0.21d 0.20d 0.30d 0.18d
mSCQ + osteoporosis + fracture 0.39 0.35d 0.34 0.22d 0.20d 0.30d 0.19d
mSCQ + EAMs + osteoporosis 0.42c 0.34 0.34d 0.20d 0.17c,d 0.28 0.18d
mSCQ + EAMs + fractures 0.42c 0.34 0.34d 0.20d 0.17c,d 0.27 0.17c,d
mSCQ + EAMs + osteoporosis
+ fractures
0.42c 0.34 0.34d 0.20d 0.17c,d 0.28 0.17c,d
RDCIb 0.44c 0.25c,d 0.22c 0.12c,d 0.08c,d 0.17c,d 0.10c,d
Patients fulfilling ASAS pSpA criteria (n = 415)
mSCQ 0.40 0.46d 0.29d 0.19d 0.29d 0.32d 0.25d
mSCQ + EAMs 0.45c 0.35c 0.29d 0.15c,d 0.22c,d 0.27c 0.19c,d
mSCQ + fractures 0.40 0.41c,d 0.30d 0.18d 0.30d 0.33d 0.26d
mSCQ + osteoporosis + fracture 0.40 0.42d 0.31 0.19d 0.32c,d 0.34d 0.26d
mSCQ + EAMs + osteoporosis 0.45c 0.36c 0.27d 0.16c,d 0.24c,d 0.28 0.19c
mSCQ + EAMs + fractures 0.45c 0.37c 0.26c,d 0.15c,d 0.24c,d 0.27c 0.19c,d
mSCQ + EAMs + osteoporosis
+ fractures
0.46c 0.37c 0.27d 0.15c,d 0.26c,d 0.29 0.20c,d
RDCIb 0.42 0.35c,d 0.23c 0.16c,d 0.25c,d 0.24c,d 0.22c,d
aWork productivity in those currently employed. bThe RDCI was calculated according to the information from the physician,
except for depression which was retrieved from the patient. cDifference of comorbidity score with mSCQ score >10%.
dDifference on correlation between axSpA and pSpA >10%. EAM: extra-articular manifestations; EQ-5D: Euroqol 5 D;
mSCQ: modified self-administered comorbidity index; RDCI: rheumatic disease comorbidity index; WPAI: work productivity
and activity impairment.
https://academic.oup.com/rheumatology 1637









niversity user on 03 August 2020
We hypothesized that adding EAMs to the mSCQ would
improve construct validity of the questionnaire. However,
except for the correlation with age, we could not show this
for other external outcomes and some correlations even
worsened. Probably, the impact of other comorbidities on
health outcomes is more important than the impact of
EAMs on these outcomes, which is in line with a previous
study that showed that EAMs do not influence long-term
health outcomes in patients with AS [23]. This was also
reflected by the fact that only a small proportion of pa-
tients answered in the mSCQ that the EAM impacted their
functioning.
In addition, osteoporosis and fractures are common
comorbidities in patients with SpA. Studies have shown
that 1962% of patients with AS have decreased BMD
and that the prevalence of spinal fractures ranges be-
tween 1% and 9% [24, 25]. Osteoporosis and fractures
may be a result of constant low-grade inflammation, dis-
ease-specific factors or immobility (such as spinal rigidity).
The agreement between self-reported osteoporosis and
fractures, and physician-reported osteoporosis and frac-
tures was weak in the present study. This might be a result
of different definitions used for osteoporosis and fractures
by patients and the study investigators. Patients may not
be aware that they suffer from osteoporosis, especially
when they do not take anti-osteoporosis drugs, or mix
up the name osteoporosis with osteoarthritis leading to
discrepancies. Also, anti-osteoporosis drugs may be
used as prophylaxis, for example because of concomitant
steroid use, and according to the study protocol this was
considered as osteoporosis, which may overestimate the
prevalence of osteoporosis as defined by the physician.
With respect to fractures, only non-traumatic fractures
were assessed in the ASAS-COMOSPA study, whereas
in the SpA-SCQ patients are asked about fractures in gen-
eral, because we felt that making a distinction between
traumatic and non-traumatic fractures would be too com-
plicated in a self-report questionnaire. Furthermore, pa-
tients may not be aware of osteoporotic vertebral
fractures (as these may be asymptomatic or symptoms
may be interpreted as SpA flare), whereas these were
scored by the study investigator. In addition to criterion
validity, we also evaluated whether adding osteoporosis
and/or fractures would improve the construct validity of
the mSCQ, but we could not show this.
This study also compared the construct validity of the
mSCQ with another validated comorbidity index, the
RDCI. The SpA-SCQ showed stronger correlations with
different health outcomes compared with the RDCI.
Likely, this is explained by the ‘additional’ question in
the SCQ on impact of comorbidities on functioning.
Furthermore, in the SCQ, patients have the option to
report up to three other non-specified medical problems.
Interestingly, the most reported ‘other’ comorbidity was
fibromyalgia, which may have significant impact on phys-
ical and mental health outcomes. This finding is in line with
recent studies that showed that fibromyalgia frequently
coexists in patients with axSpA [26, 27]. Last, the SCQ
is based on self-report, whereas for the RDCI medical
record data were used. These data may also include
comorbidities the patient suffered from in the past, but
that do no longer have an impact on health outcomes.
Although the RDCI had proven validity, we cannot ignore
that correlations of the mSCQ with different health out-
comes were consistently stronger, and the mSCQ is
therefore preferred when these outcomes are studied.
In an era with increasing multinational research, validity
of a questionnaire across countries is of interest.
Therefore, the construct and criterion validity of the
mSCQ were compared between different regions in the
world, which showed significant differences. For example,
the correlation between comorbidity scores and several
constructs, such as physical function and quality of life,
was weaker in Asia and North Africa compared with
Europe and North and South America. Importantly, there
were already considerable differences in baseline charac-
teristics of physical function and quality of life between the
different regions. Most likely, cultural aspects both influ-
ence patient-reported outcomes and the way comorbid-
ities influence these outcomes.
Strengths of the present study are the large number of
patients and the multi-national character of the study. A
limitation of the study is that we cannot exclude that the
study investigators used the answers of the patients to fill
out the physician case report form. This may have over-
estimated the agreement between self-reported and
physician-reported comorbidities. A second limitation is
the slightly different definitions of osteoporosis and frac-
tures in the SpA-SCQ and in the investigator part of the
study. Therefore, the weak agreement between both may
be an underestimation of the actual criterion validity.
In summary, the mSCQ has been shown to be valid in a
large number of patients with SpA from different coun-
tries. The agreement between patient-reported and phys-
ician-reported EAMs was high, but low for osteoporosis
and fractures. The construct validity of the mSCQ did not
improve by adding EAMs or osteoporosis and fractures to
the questionnaire. Therefore, we do not recommend
including these extra questions in the mSCQ in patients
with SpA. In future studies in patients with SpA, the mSCQ
can be used to assess the impact of comorbidities on
health outcomes.
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